International Journal of Rheumatic Diseases · 2019 · 15 citations · 22 references
PharmacyClinical SciencesHealth AssessmentHealth PsychologyRheumatologyHealth Status MeasurementHealth-related Quality Of LifeHealth-related Quality Of Life MeasurementPsoriatic ArthritisSymptom AssessmentSymptom Burden AssessmentDisease Activity MeasurementDisease Severity IndexEuroqol Five DimensionsHealth Utility EstimationHealth Utility MappingMinimal Disease ActivityPatient-reported Functional StatusPsoriatic Disease
Abstract Aim To identify factors associated with the EuroQol‐5 Dimensions‐5 levels (EQ‐5D‐5L) and patient acceptable symptom state (PASS) and to estimate health utility (HU) in Thai patients with psoriatic arthritis (PsA). Methods A cross‐sectional study of consecutive PsA patients visiting Siriraj Hospital was performed between 31 May, 2012 and 31 March, 2016. Data of patient demographics, HU outcomes (Thai EQ‐5D‐5L), disease activity (Disease Activity Index for Psoriatic Arthritis [DAPSA], the Clinical DAPSA [cDAPSA], the minimal disease activity [MDA]), and the Health Assessment Questionnaire (HAQ) were collected. Regression analyses were used to explore factors associated with each EQ‐5D domain, HU, and PASS. Results Of 129 PsA patients, the mean age was 47.6 years; 53.5% were male. The mean HU was 0.76. Univariable analysis showed lower disease activity and less impaired function were significantly associated with higher HU and no to mild problem in each EQ‐5D domain. Multivariable analysis showed HAQ and disease activity indices (cDAPSA, DAPSA, MDA) adjusting for age, had good goodness‐of‐fit to HU (adjusted R 2 : 0.63‐0.65). Patients answering “yes” to PASS had significantly longer disease duration of PsA, higher HU, lower disease activity, less disability, and were more often married than those answering “no” to PASS. Pain problem was the most important association to PASS adjusting for other domains and age. Conclusions Disease activity and functional status in PsA patients were significant factors related to HU and PASS. To improve quality of life, the goal of treatment should be achieving remission, improving function, and controlling pain.
22
EuroQol - a new facility for the measurement of health-related quality of life
Health Policy · 1990 · 15.8K citations
Josef S Smolen, Monika Schöls, Jürgen Braun et al. · Annals of the Rheumatic Diseases · 2017 · 676 citations · Full text